Biopharmaceutical company Wave Life Sciences has gone public at the middle of its range just nine months after closing its $18m SNBL-led series A round.
Wave Life Sciences, a US-based nucleic acid therapeutic developer backed by contract research organisation Shin Nippon Biomedical Laboratories (SNBL), raised $102m in an initial public offering on Nasdaq yesterday.
Wave priced 6.375 million shares at $16.00 each, the middle of the IPO’s $15 to $17 range. Almost 960,000 additional shares are available for the offering’s underwriters to buy in the next 30 days, which could raise the size of the offering to $117.3m.
Founded in 2014, Wave has built…
